DK2909181T3 - PKM2-modulatorer og fremgangsmåder til anvendelse deraf - Google Patents
PKM2-modulatorer og fremgangsmåder til anvendelse derafInfo
- Publication number
- DK2909181T3 DK2909181T3 DK13847643.7T DK13847643T DK2909181T3 DK 2909181 T3 DK2909181 T3 DK 2909181T3 DK 13847643 T DK13847643 T DK 13847643T DK 2909181 T3 DK2909181 T3 DK 2909181T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- pkm2
- modulators
- pkm2 modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261714659P | 2012-10-16 | 2012-10-16 | |
US201361875855P | 2013-09-10 | 2013-09-10 | |
PCT/US2013/065296 WO2014062838A2 (en) | 2012-10-16 | 2013-10-16 | Pkm2 modulators and methods for their use |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2909181T3 true DK2909181T3 (da) | 2017-11-20 |
Family
ID=50488890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13847643.7T DK2909181T3 (da) | 2012-10-16 | 2013-10-16 | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
Country Status (6)
Country | Link |
---|---|
US (5) | US9394257B2 (da) |
EP (1) | EP2909181B1 (da) |
JP (7) | JP6243918B2 (da) |
DK (1) | DK2909181T3 (da) |
ES (1) | ES2644758T3 (da) |
WO (1) | WO2014062838A2 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2909181B1 (en) * | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
US20200237766A1 (en) * | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
KR20210141621A (ko) * | 2019-03-22 | 2021-11-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법 |
US20220162200A1 (en) * | 2019-03-22 | 2022-05-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Pkm2 modulators and methods for their use |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP2861087B2 (ja) * | 1989-08-08 | 1999-02-24 | 三菱化学株式会社 | N―アシル‐5‐ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
IT1255527B (it) * | 1992-09-29 | 1995-11-09 | Mini Ricerca Scient Tecnolog | Pirazolcarbossammidi ad attivita' insetticida ed acaricida |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
DE19600097C1 (de) | 1996-01-03 | 1997-07-31 | Siemens Ag | Verfahren und Vorrichtung zur Bestimmung einer Flüssigkeitshöhe mit Hilfe von Ultraschallimpulsen |
PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
ID19430A (id) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | Senyawa senyawa heterosiklik |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
WO1998054093A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
KR100372138B1 (ko) | 1997-08-08 | 2003-02-14 | 화이자 프로덕츠 인코포레이티드 | 아릴옥시아릴설포닐아미노 하이드록삼산 유도체 |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
IL139934A (en) | 1998-05-29 | 2007-10-31 | Sugen Inc | History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
HUP0104693A3 (en) | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
JP2001172261A (ja) * | 1999-12-20 | 2001-06-26 | Mitsubishi Chemicals Corp | ピラゾールカルボン酸アミド類、およびこれを有効成分とする殺虫、殺ダニ剤 |
MY130363A (en) | 2000-02-15 | 2007-06-29 | Sugen Inc | "pyrrole substituted 2-indolinone protein kinase inhibitors" |
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422380C (en) * | 2000-09-15 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
CN1511142A (zh) * | 2001-04-06 | 2004-07-07 | 日本农药株式会社 | 吡唑酰胺衍生物及用于制备该衍生物的中间体、以该衍生物为活性成分的有害生物防治剂 |
JP2002363164A (ja) * | 2001-04-06 | 2002-12-18 | Mitsubishi Chemicals Corp | ピラゾールカルボキサミド類、その中間体およびこれを有効成分とする有害生物防除剤 |
PL221491B1 (pl) | 2002-03-08 | 2016-04-29 | Eisai R&D Man Co | Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków |
PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
AP2007004198A0 (en) * | 2005-04-08 | 2007-10-31 | Pfizer Prod Inc | Bicyclic [3.1.0] heteroaryl amides as type I glycine transport inhibitors |
EP1884513A4 (en) * | 2005-05-23 | 2010-04-28 | Japan Tobacco Inc | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME |
CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US8552050B2 (en) | 2007-08-16 | 2013-10-08 | Beth Israel Deaconess Medical Center | Activators of pyruvate kinase M2 and methods of treating disease |
JPWO2009028280A1 (ja) * | 2007-08-29 | 2010-11-25 | 三井化学アグロ株式会社 | ピラゾールカルボン酸誘導体及びその製造方法、並びに殺菌剤 |
KR101584823B1 (ko) | 2007-09-12 | 2016-01-22 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법 |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
EP2346831B1 (en) | 2008-11-17 | 2015-01-07 | Boehringer Ingelheim International GmbH | Heteroaryl diamide compounds useful as mmp-13 inhibitors |
EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
JP5756457B2 (ja) * | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法 |
ES2619557T3 (es) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
US8349832B2 (en) | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
CN105482129B (zh) | 2010-09-30 | 2018-07-27 | 黄奇英 | 抗癌萃取物及化合物 |
WO2012056319A1 (en) | 2010-10-27 | 2012-05-03 | Dynamix Pharmaceuticals Ltd. | Sulfonamides for the modulation of pkm2 |
ES2564952T3 (es) * | 2010-12-17 | 2016-03-30 | Agios Pharmaceuticals, Inc. | Nuevos derivados de N-(4-(azetidina-1-carbonil)fenil)-(hetero-)arilsulfonamida como moduladores de piruvato quinasa M2 (PKM2) |
EP2655350B1 (en) | 2010-12-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP2497775A1 (en) | 2011-03-11 | 2012-09-12 | Ruprecht-Karls-Universität Heidelberg | Ferrocene-based compounds and their use as ROS regulating prodrugs |
WO2012160447A1 (en) * | 2011-05-25 | 2012-11-29 | Dynamix Pharmaceuticals Ltd. | 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases |
WO2013005157A1 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer |
EP2909181B1 (en) * | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
NZ707778A (en) | 2012-11-08 | 2019-03-29 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions and their use as pkm2 modulators |
US9447054B2 (en) | 2014-01-15 | 2016-09-20 | Korea Institute Of Radiological & Medical Sciences | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient |
-
2013
- 2013-10-16 EP EP13847643.7A patent/EP2909181B1/en active Active
- 2013-10-16 JP JP2015537799A patent/JP6243918B2/ja active Active
- 2013-10-16 ES ES13847643.7T patent/ES2644758T3/es active Active
- 2013-10-16 US US14/435,976 patent/US9394257B2/en active Active
- 2013-10-16 WO PCT/US2013/065296 patent/WO2014062838A2/en active Application Filing
- 2013-10-16 DK DK13847643.7T patent/DK2909181T3/da active
-
2016
- 2016-06-15 US US15/183,581 patent/US10207996B2/en active Active
-
2017
- 2017-10-20 JP JP2017203963A patent/JP6526767B2/ja active Active
-
2018
- 2018-10-01 JP JP2018186629A patent/JP2019023209A/ja not_active Withdrawn
- 2018-12-19 US US16/226,599 patent/US10472328B2/en active Active
-
2019
- 2019-09-26 US US16/584,912 patent/US10766865B2/en active Active
-
2020
- 2020-03-03 JP JP2020035656A patent/JP2020105190A/ja not_active Withdrawn
- 2020-03-03 JP JP2020035657A patent/JP2020097631A/ja not_active Withdrawn
- 2020-07-15 US US16/930,254 patent/US20210002233A1/en not_active Abandoned
-
2021
- 2021-07-21 JP JP2021120679A patent/JP7128331B2/ja active Active
- 2021-08-06 JP JP2021129580A patent/JP2021181467A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014062838A3 (en) | 2014-10-16 |
JP2021176878A (ja) | 2021-11-11 |
WO2014062838A2 (en) | 2014-04-24 |
JP2020097631A (ja) | 2020-06-25 |
US20190119219A1 (en) | 2019-04-25 |
JP2018009036A (ja) | 2018-01-18 |
US20200109120A1 (en) | 2020-04-09 |
JP2020105190A (ja) | 2020-07-09 |
JP2015536325A (ja) | 2015-12-21 |
EP2909181B1 (en) | 2017-08-09 |
EP2909181A2 (en) | 2015-08-26 |
US10766865B2 (en) | 2020-09-08 |
EP2909181A4 (en) | 2016-03-23 |
US10472328B2 (en) | 2019-11-12 |
JP7128331B2 (ja) | 2022-08-30 |
US20210002233A1 (en) | 2021-01-07 |
JP6526767B2 (ja) | 2019-06-05 |
ES2644758T3 (es) | 2017-11-30 |
JP2021181467A (ja) | 2021-11-25 |
JP2019023209A (ja) | 2019-02-14 |
JP6243918B2 (ja) | 2017-12-06 |
US20150344436A1 (en) | 2015-12-03 |
US20170015631A1 (en) | 2017-01-19 |
US9394257B2 (en) | 2016-07-19 |
US10207996B2 (en) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2850202T3 (da) | Fremgangsmåder og grupper | |
DK2854883T3 (da) | Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf | |
DK2925782T3 (da) | Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3196022T3 (da) | Trykningssystem og fremgangsmåde | |
DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
DK2872419T3 (da) | Fordelingsbeholder og tilsvarende fremgangsmåde | |
DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
DK2838917T3 (da) | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler | |
DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
DK2906696T3 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
DK2934836T3 (da) | Splitting apparatus | |
DK2844292T3 (da) | ST2L-antagonister og fremgangsmåder til anvendelse | |
DK3144249T3 (da) | Beholder med styreelement til klæbemiddel og fremgangsmåde | |
DK2970205T3 (da) | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf | |
DK2672967T3 (da) | Forbindelser og fremgangsmåder til kinasemodulering og indikationer derfor | |
DK2817287T3 (da) | Trialkyl kationisk lipid og metoder til anvendelse deraf | |
BR112014030410A2 (pt) | inibidores de pirazolopirimidona e pirazolopiridona de tanquirase | |
BR112015007125A2 (pt) | aparelho e método | |
DK3930322T3 (da) | Fremgangsmåder og anordninger til kodning | |
DK3379339T3 (da) | Procespatron og billeddannende indretning | |
DK2922955T3 (da) | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression | |
DK3063300T3 (da) | Mikropeptider og anvendelse deraf til modulering af genekspression |